The role and efficacy of Ofatumumab

Ofatumumab injection is used in combination with chlorambucil to treat a type of white blood cell cancer called chronic lymphocytic leukemia (CLL) in patients who have not received any treatment in the past. It is also used in combination with fludarabine and cyclophosphamide to treat patients with relapsed CLL. This drug is also used in patients with CLL who have been unsuccessfully treated with other drugs (such as alemtuzumab, fludarabine).

Ofatumumab injection is also used to treat relapsing forms of multiple sclerosis(MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This drug will not cure multiple sclerosis, but it may slow some of the disabling effects and reduce the number of relapses of the disease. Ofatumumab interferes with the growth of cancer cells, which are eventually destroyed by the body. Because the growth of normal body cells may also be affected by ofatumumab, other adverse reactions may occur, some of which may be serious, such as rashes, etc., which may not be serious but may cause concern. Some adverse reactions may appear months or years after taking the medication.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.